Dompe to pay $32 million over Medicare co-pay scheme for eye drug

Dompe U.S. Inc. has agreed to pay $32 million to resolve allegations of violating the Anti-Kickback Statute and the False Claims Act. The company is the American subsidiary of Italy-based Dompe farmaceutici S.p.A. The Justice Department announced the settlement, which addresses a scheme related to Medicare co-pays for an eye drug.

• Dompe U.S. Inc. will pay $32 million.
• The settlement resolves allegations of violating the Anti-Kickback Statute and the False Claims Act.
• Dompe U.S. Inc. is the American subsidiary of Italy-based Dompe farmaceutici S.p.A.
• The allegations concern a scheme involving Medicare co-pays for an eye drug.